APO-AZATHIOPRINE 50 MG
AZATHIOPRINE : 50 MG · DIN 02242907 · APOTEX INC
Health Canada status: MARKETED
What is APO-AZATHIOPRINE?
APO-AZATHIOPRINE 50 MG contains AZATHIOPRINE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02242907, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Oct-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-AZATHIOPRINE used for?
APO-AZATHIOPRINE (azathioprine tablets) is indicated as an adjunct for the prevention of rejection in renal homotransplantation. APO-AZATHIOPRINE is indicated only in adult patients meeting criteria for classic or definite rheumatoid arthritis as specified by the American Rheumatism Association. APO-AZATHIOPRINE should be restricted to patients with severe, active and erosive disease not responsive to conventional management including rest, acetylsalicylic acid or other non-steroidal drugs, or with disease-modifying antirheumatic drugs (DMARD’s).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242907 |
|---|---|
| Brand name | APO-AZATHIOPRINE |
| Generic / active ingredient | AZATHIOPRINE : 50 MG |
| Manufacturer | APOTEX INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AX01 AZATHIOPRINE |
| AHFS class | 90:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Oct-2000 |
| Original market date | 2000-10-17 00:00:00 |
How is it administered?
Renal Transplant: Initial 3-5 mg/kg daily; maintenance 1-3 mg/kg daily. Rheumatoid Arthritis: Initial 1.0 mg/kg (50-100 mg) daily; may increase by 0.5 mg/kg daily to max 2.5 mg/kg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
bottles of 100 tablets
Contraindications
Hypersensitivity to azathioprine or any ingredient in the formulation. Patients with a history of hypersensitivity to 6-mercaptopurine should not be prescribed azathioprine.
Warnings and precautions
Mutagenic and carcinogenic; increased risk of neoplasia (lymphoma, skin cancer). Severe leukopenia/thrombocytopenia. Macrophage activation syndrome. Increased susceptibility to infection.
What can be used instead?
Other Canadian products sharing ATC code L04AX01 AZATHIOPRINE. 3 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IMURAN | 50 MG | TABLET | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00004596 |
| TEVA-AZATHIOPRINE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02236819 |
| AZATHIOPRINE | 50 MG | TABLET | BDH INC. | CANCELLED POST MARKET | DIN 02235352 |
| AZATHIOPRINE | 50 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02343002 |
| AZATHIOPRINE SODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02231575 |
| AZATHIOPRINE-50 | 50 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02243371 |
| IMURAN | 50 MG | POWDER FOR SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | DIN 02244895 |
| IMURAN INJ 100MG | 100 MG | POWDER FOR SOLUTION | GLAXO WELLCOME INC. | CANCELLED POST MARKET | DIN 00337854 |
| MYLAN-AZATHIOPRINE | 50 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02231491 |
| NTP-AZATHIOPRINE | 50 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02358573 |
Who else supplies AZATHIOPRINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AZATHIOPRINE appears in 113 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.